Verteporfin
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
- Verteporfin
- Verteporfin: From Macular Degeneration to Mitochondrial Oxidative Phosphorylation Disorder Due to Nuclear DNA Anomalies
Verteporfin: From Macular Degeneration to Mitochondrial Oxidative Phosphorylation Disorder Due to Nuclear DNA Anomalies
One-Sentence Summary
Verteporfin is a light-activated photosensitizer, originally used to treat macular degeneration. The TxGNN model predicts it may be effective for mitochondrial oxidative phosphorylation disorder due to nuclear DNA anomalies, but there are currently 0 clinical trials and 0 publications supporting this direction. The prediction rests on the model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Macular degeneration |
| Predicted New Indication | Mitochondrial oxidative phosphorylation disorder due to nuclear DNA anomalies |
| TxGNN Prediction Score | 99.49% |
| Evidence Level | L5 |
| US Market Status | Cancelled only (no currently valid licenses) |
| Number of NDAs | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on known information, verteporfin is a photosensitizer activated by non-thermal red light (about 689 nm). Activation generates reactive oxygen species and causes local vascular occlusion, which is the basis of its use in macular degeneration.
Preclinical work also reports that verteporfin inhibits YAP-TEAD signaling and may affect autophagy. If this holds, modulating YAP/Hippo signaling or autophagy/mitophagy could be a speculative route to mitochondrial disease. However, the photodynamic action produces oxidative stress, which could instead worsen oxidative phosphorylation dysfunction.
The link between the original indication (a retinal vascular condition) and the predicted one (an inherited mitochondrial disorder) is therefore weak. The prediction is unvalidated, and whether it would help or harm is unclear. The high TxGNN score (99.49%) reflects knowledge-graph patterns only, not clinical or experimental evidence.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| NDA021119 | Visudyne (Bausch & Lomb Incorporated; status: cancelled) | Injection, powder, lyophilized, for solution | Not listed in the data compiled for this report |
Safety Considerations
- Contraindications suggested by the knowledge graph (from drug-disease relationship data, not from label text): inherited porphyria, porphyrin metabolism disease, porphyria, liver disease, gallbladder disease.
- Drug Interactions: The interaction query returned 100 records, and 20 are shown in the data compiled for this report. Almost all are rated Moderate, with one Minor (polymyxin B). The main groups are:
- Tetracyclines: doxycycline, tetracycline and minocycline, including topical forms
- Sulfonylurea antidiabetics: chlorpropamide, glimepiride, glipizide, glyburide, tolazamide, tolbutamide and acetohexamide
- Others: acetylsalicylic acid, levofloxacin, mannitol, sulfasalazine, beta carotene and papaverine
Many of these (tetracyclines, sulfonylureas, fluoroquinolones) are known photosensitizing agents, which suggests an additive photosensitivity concern. This is an inference and not confirmed by the data.
Package insert warnings and contraindications were not available. Please refer to the package insert for full safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by a model score, with no clinical trials or literature (Evidence Level L5). The drug’s photodynamic oxidative stress could worsen mitochondrial dysfunction, so the direction of effect is uncertain. The only US NDA is cancelled, and the knowledge graph flags several relevant contraindications (porphyria, liver and gallbladder disease).
To proceed, the following is needed:
- Package insert warnings and contraindications (a blocking gap for safety screening)
- Mechanism of action data to test the mechanistic link
- Preclinical studies in mitochondrial disease models, including mitochondrial function and oxidative stress readouts, to establish whether the effect is beneficial or harmful
- Assessment of route and light-activation feasibility for a systemic or non-ocular mitochondrial disorder
- A literature search to confirm whether any supporting studies exist
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.